Loading
A phase 1/2 trial of AT101 in hodgkin lymphoma and non-hodgkin lymphoma, run by AbClon, now recruiting.
Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT05338931 by AbClon, with 82 participants planned, started 2022-03-15 and due to reach its primary completion in 2030-03-15. Interventions recorded: AT101(Anti-CD19 Chimeric Antigen Receptor T cell). Conditions listed: B-cell Non Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.